z-logo
open-access-imgOpen Access
Effect of Alternate Treatment with Intravitreal Corticosteroid and Anti-VEGF for Macular Edema Secondary to Retinal Vein Occlusion
Author(s) -
Young Hwan Bae,
Seong Mi Kim,
Jin Young Kim,
So Hyun Bae,
Hakyoung Kim,
Dae Joong
Publication year - 2021
Publication title -
journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 40
eISSN - 2090-0058
pISSN - 2090-004X
DOI - 10.1155/2021/5948113
Subject(s) - medicine , macular edema , retinal vein , ophthalmology , central retinal vein occlusion , occlusion , vegf receptors , corticosteroid , retinal , surgery
Purpose To evaluate whether treatment with intravitreal corticosteroid and anti-vascular endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of macular edema (ME) caused by retinal vein occlusion (RVO).Methods This dual-center retrospective study included 112 eyes with treatment-naïve ME secondary to RVO that were alternately treated with intravitreal corticosteroid and anti-VEGF injections (33 eyes, alternate group) or treated only with intravitreal anti-VEGF injections (79 eyes, anti-VEGF group) on a pro re nata basis.Results During the 12-month follow-up period, the alternate group achieved a visual acuity gain of 0.39 logMAR, while the anti-VEGF group achieved a gain of 0.21 logMAR ( P =0.042). The alternate group demonstrated a reduction in the central macular thickness of 229.9- μ m, while the anti-VEGF group achieved a reduction of 220.1 μ m ( P =0.887). The alternate group required an average of 5.2 injections, while the anti-VEGF received 4.2 injections ( P < 0.001). In a propensity score-matched cohort to compensate for the differences in the injection numbers between the two groups, the alternate group achieved a better visual acuity gain than the anti-VEGF group at month 12 (0.39 logMAR vs. 0.17 logMAR, P =0.048).Conclusions In ME secondary to RVO, treatment with intravitreal corticosteroid and anti-VEGF injections alternately resulted in a more favorable visual outcome compared with intravitreal anti-VEGF monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom